Stock COR CENCORA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cencora, Inc.

Equities

COR

US03073E1055

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-17 pm EDT 		5-day change 1st Jan Change
222.1 USD +0.12% Intraday chart for Cencora, Inc. -1.10% +8.15%
May. 17 JPMorgan Adjusts Price Target on Cencora to $280 From $270 MT
May. 08 Jefferies Adjusts Price Target on Cencora to $230 From $235 MT

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,151 19,785 24,820 28,048 36,148 44,302 - -
Enterprise Value (EV) 1 17,950 19,307 28,957 30,363 38,343 45,378 43,880 40,081
P/E ratio 20.4 x -5.82 x 16.2 x 16.8 x 21.1 x 21.7 x 18.6 x 16.4 x
Yield 1.94% 1.71% 1.49% 1.36% - 0.93% 0.95% 1%
Capitalization / Revenue 0.1 x 0.1 x 0.12 x 0.12 x 0.14 x 0.15 x 0.14 x 0.13 x
EV / Revenue 0.1 x 0.1 x 0.14 x 0.13 x 0.15 x 0.16 x 0.14 x 0.12 x
EV / EBITDA 7.63 x 7.77 x 9.73 x 8.55 x 10.4 x 11.2 x 10.1 x 8.7 x
EV / FCF 8.83 x 10.5 x 13 x 13.8 x 11.1 x 18.2 x 14.9 x 12.4 x
FCF Yield 11.3% 9.52% 7.7% 7.27% 9.01% 5.49% 6.7% 8.07%
Price to Book 5.91 x -19.4 x 111 x 401 x - 26.6 x 14.4 x 8.94 x
Nbr of stocks (in thousands) 208,326 204,142 207,787 207,258 200,854 199,452 - -
Reference price 2 82.33 96.92 119.4 135.3 180.0 222.1 222.1 222.1
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 179,589 189,894 213,989 238,587 262,173 290,321 310,238 328,874
EBITDA 1 2,354 2,485 2,977 3,553 3,702 4,034 4,326 4,608
EBIT 1 2,051 2,204 2,648 3,163 3,289 3,641 3,882 4,124
Operating Margin 1.14% 1.16% 1.24% 1.33% 1.25% 1.25% 1.25% 1.25%
Earnings before Tax (EBT) 1 967.1 -5,294 2,222 2,183 2,161 2,465 2,709 3,002
Net income 1 855.4 -3,409 1,540 1,699 1,745 2,011 2,327 2,576
Net margin 0.48% -1.8% 0.72% 0.71% 0.67% 0.69% 0.75% 0.78%
EPS 2 4.040 -16.65 7.390 8.040 8.530 10.24 11.96 13.56
Free Cash Flow 1 2,034 1,837 2,228 2,207 3,453 2,493 2,941 3,234
FCF margin 1.13% 0.97% 1.04% 0.92% 1.32% 0.86% 0.95% 0.98%
FCF Conversion (EBITDA) 86.4% 73.94% 74.85% 62.11% 93.27% 61.81% 67.99% 70.18%
FCF Conversion (Net income) 237.77% - 144.71% 129.9% 197.85% 123.95% 126.38% 125.51%
Dividend per Share 2 1.600 1.660 1.780 1.840 - 2.064 2.114 2.220
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 59,629 57,719 60,065 61,174 62,847 63,457 66,947 68,922 72,253 68,414 73,575 75,775 76,648 73,053 78,748
EBITDA 1 845.6 1,014 853.9 839.4 833.8 1,033 927.4 907.3 990.6 1,141 972.8 960.2 1,044 1,196 1,041
EBIT 1 749.1 916.6 756.2 741.5 733.7 932.1 822.3 801 885.7 1,034 869 852.2 935.4 1,113 932.2
Operating Margin 1.26% 1.59% 1.26% 1.21% 1.17% 1.47% 1.23% 1.16% 1.23% 1.51% 1.18% 1.12% 1.22% 1.52% 1.18%
Earnings before Tax (EBT) 1 596.2 728.2 476.3 382.3 593.5 512.1 608.8 446.4 783.4 467.1 602.5 591.7 649.1 826.5 684.2
Net income 1 449.1 548 407 294.7 479.7 435.4 479.6 350.6 601.5 420.8 493.9 469.7 570.1 706.4 575.6
Net margin 0.75% 0.95% 0.68% 0.48% 0.76% 0.69% 0.72% 0.51% 0.83% 0.62% 0.67% 0.62% 0.74% 0.97% 0.73%
EPS 2 2.130 2.590 1.920 1.400 2.330 2.130 2.350 1.720 2.980 2.090 2.587 2.549 2.915 3.573 3.015
Dividend per Share 2 0.4600 0.4600 0.4600 0.4600 0.4850 0.4850 0.4850 - - - 0.5173 0.5173 0.5205 0.5205 0.5205
Announcement Date 2/2/22 5/4/22 8/3/22 11/3/22 2/1/23 5/2/23 8/2/23 11/2/23 1/31/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 799 - 4,137 2,315 2,195 1,076 - -
Net Cash position 1 - 478 - - - - 422 4,221
Leverage (Debt/EBITDA) 0.3393 x - 1.39 x 0.6515 x 0.593 x 0.2667 x - -
Free Cash Flow 1 2,034 1,837 2,228 2,207 3,453 2,493 2,941 3,234
ROE (net income / shareholders' equity) 28.3% 152% - 39,497% 473% 203% 115% 78.9%
ROA (Net income/ Total Assets) 2.23% 3.93% 3.03% 2.98% 2.93% 3.54% 3.75% 3.87%
Assets 1 38,421 -86,793 50,806 56,949 59,560 56,774 62,094 66,578
Book Value Per Share 2 13.90 -4.990 1.070 0.3400 - 8.350 15.50 24.80
Cash Flow per Share 2 11.10 10.80 12.80 12.80 19.10 16.40 21.90 22.70
Capex 1 310 370 438 496 458 483 532 564
Capex / Sales 0.17% 0.19% 0.2% 0.21% 0.17% 0.17% 0.17% 0.17%
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cencora, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
222.1 USD
Average target price
255.1 USD
Spread / Average Target
+14.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
CENCORA, INC. Stock Cencora, Inc.
+8.15% 44.3B
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.43% 181B
MEDTRONIC PLC Stock Medtronic plc
+4.30% 114B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.09% 68.29B
DEXCOM, INC. Stock DexCom, Inc.
+5.86% 52.24B
HOYA CORPORATION Stock Hoya Corporation
+7.52% 42.73B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+25.54% 32.52B
TERUMO CORPORATION Stock Terumo Corporation
+17.85% 26.02B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+1.00% 25.91B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-1.25% 24.72B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. COR Stock
  4. Financials Cencora, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW